Crinetics Pharmaceuticals, Inc.
CRNX
$35.20
$0.732.12%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 7.53% | 6.10% | |||
| Gross Profit | -7.53% | -6.83% | |||
| SG&A Expenses | 8.83% | 4.24% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.91% | 5.55% | |||
| Operating Income | -7.91% | -6.06% | |||
| Income Before Tax | -4.90% | -3.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.90% | -3.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.90% | -3.74% | |||
| EBIT | -7.91% | -6.06% | |||
| EBITDA | -7.96% | -6.09% | |||
| EPS Basic | 8.17% | -2.35% | |||
| Normalized Basic EPS | 8.17% | -2.34% | |||
| EPS Diluted | 8.17% | -2.35% | |||
| Normalized Diluted EPS | 8.17% | -2.34% | |||
| Average Basic Shares Outstanding | 14.24% | 1.37% | |||
| Average Diluted Shares Outstanding | 14.24% | 1.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
